Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545027 | 0.98 | GLA (0.96) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| SCHEMBL11428443 | 0.96 | GLA (0.92) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1094998 | 0.96 | GLA (1.00) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| Bromide SCHEMBL28460623 | 0.96 | GLA (0.92) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| SCHEMBL8207081 | 0.96 | GLA (0.92) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| Water SCHEMBL29101661 | 0.94 | GLA (0.88) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| SCHEMBL10987121 | 0.90 | GLA (0.81) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| SCHEMBL465026 | 0.85 | GLA (0.74) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| SCHEMBL4789962 | 0.85 | GLA (0.74) | GLAHSD17B10ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1127696 | 0.83 | GLA (0.78) | GLAHSD17B10ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8697716-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| US-20140005225-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-02 | — | — | US | disclosed |
| EP-2397138-B1 | Aromatic amide derivatives as C-KIT kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-11 | — | — | EP | disclosed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-07 | — | — | US | disclosed |
| US-7795279-B2 | Method of inhibiting FLT3 kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007124369-A2 | METHOD OF INHIBITING C KIT KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | GLA 1715/4885HSD17B10 4835/4885ALDH1A1 4789/4885 |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | SOST, CALCB, CALCA | GLA 232/4885HSD17B10 3813/4885ALDH1A1 3354/4885 |
| US-20140005225-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | GLA 1406/4885HSD17B10 3330/4885ALDH1A1 2215/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | GLA 3142/4885HSD17B10 1853/4885ALDH1A1 1900/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | GLA 1715/4885HSD17B10 4835/4885ALDH1A1 4789/4885 |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | GLA 1406/4885HSD17B10 3330/4885ALDH1A1 2215/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | GLA 3449/4885HSD17B10 1714/4885ALDH1A1 2471/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | GLA 1406/4885HSD17B10 3330/4885ALDH1A1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.